


CERTIFICATE OF HAND DELIVERY			
I hereby certify that this correspondence is being deposited via hand delivery to the U.S. Patent and Trademark Office, Art Unit 1631. Examiner Marjorie A. Moran			
Typed or Printed Name	Heather Samra		
Signature		Date	2/25/04
INFORMATION DISCLOSURE STATEMENT Address to: Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450		Attorney Docket Confirmation No.	UCAL-107CIP2 2678
		First Named Inventor	BISTRUP, ANNETTE
		Application Number	09/645,078
		Filing Date	August 23, 2000
		Group Art Unit	1631
		Examiner Name	MORAN, MARJORIE A.
		Title: "GLYCOSYL SULFOTRANSFERASE-3"	

Sir:

This is an Information Disclosure Statement (IDS) submitted for the Examiner's consideration. This IDS is being filed concurrently with a Request for Continued Examination.


A Form SB08A listing the references accompanies this paper. Applicants would appreciate the Examiner initialing and returning the form to indicate that the references have been reviewed and made of record.

Applicants wish to bring to the Examiner's attention the following disclosure relating to the nucleic acid cloning of GST-3 that is found in the specification for USSN 09/645,078 at page 44, lines 5-9. Figure 1 is attached for the Examiner's convenience.

Since no PCR-step was used in generating the full length HEC-GLCNAC6ST Lifeseq EST Incyte #2167407 (in contrast to the Cap-finder methodology employed in generation of our HEV-library), the HEC-GLCNAC6ST sequence obtained from Incyte #2617407 is free of PCR errors. The sequence is provided in SEQ ID NO:01 and shown in FIG. 1.

Rec'd by
John J. Doll, Director
Technology Center 1600

FEB 26 2004



Applicants also wish to bring to the Examiner's attention an inventors' publication, Bistrup et al., 1999, J. Cell Biol. Vol. 145: 899-910, listed on the accompanying form SB08A. This reference lists inventors A. Bistrup, S. Rosen and S. Hemmerich as co-authors, and describes the methods for the nucleic acid cloning of HEC-GLCNAC6ST. The Examiner is invited to review the entire reference and in particular, Applicants wish to bring to the Examiner's attention the "Results" section at pages 902 and 903 which describes the identification of cDNAs. In particular, Applicants bring to the Examiner's attention the following excerpts from page 902, right column and page 903, left column, respectively:

After two additional rounds of screening, a single positive clone was obtained. The cDNA corresponding to this clone contains a single open reading frame of 1,158 nucleotides. The cDNA is apparently full length as indicated by the presence of an upstream stop codon and a Kozak sequence surrounding the first ATG, and a poly(A) tail at the 3' end.

One EST was identified in the LifeSeq database that mapped to the new gene at the 5' end of the protein coding region. When the clone (no. 2617407, derived from gall bladder) corresponding to this EST was fully sequenced, its sequence completely matched the original cDNA sequence within the coding region.


Pursuant to M.P.E.P. section 724.02, Applicants submit concurrently herewith an envelope marked as proprietary that contains the nucleic acid sequence for Incyte Lifeseq clone no. 2620445; and Incyte Lifeseq clone no. 2617407.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

No fee is believed to be required with the filing of the Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, the Office is hereby authorized to charge any additional fees which may be required by this paper or any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21, or to credit any overpayment, to our Deposit Account No. 50-0815, Order No. UCAL-107CIP2 may be charged thereon.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: Feb. 24, 2004

By: 
Paula A. Borden, Reg. No. 42,344

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650)327-3231

F:\DOCUMENT\UCAL\107cip2\ids.doc

Please type a plus sign (+) inside this box →



Rec'd by
FEB 26 2004
J. Doll

John J. Doll, Director
Technology Center 1600

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	09/645,078	
			Filing Date	August 23, 2000	
			First Named Inventor	BISTRUP, ANNETTE	
			Group Art Unit	1631	
			Examiner Name	MORAN, MARJORIE A.	
Sheet	1	of	1	Attorney Docket Number	UCAL107CIP2

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials ¹	Cite No. ¹	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	† ⁸
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
			WO 00/14251		Incyte Pharmaceuticals, Inc.	03-16-2000		
			WO 00/58473		Curagen Corporation	10-05-2000		
			WO 01/85177		The Burnham Institute	11-15-2001		
			EP 1130094		Helix Research Institute	09-05-2001		

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	† ²
		Bistrup et al., 1999, <u>J. Cell Biol.</u> Vol. 145: 899-910	
		Lifeseq clone # 2620445	
		Lifeseq clone# 2617407	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.